Valuation: Newron Pharmaceuticals S.p.A.

Market Cap 186M 209M 174M 158M 298M 20.14B 302M 2.1B 814M 10.26B 785M 768M 32.94B P/E 2026 *
-6.7x
P/E 2027 * 250x
Enterprise Value 200M 225M 187M 170M 321M 21.68B 325M 2.26B 876M 11.04B 845M 827M 35.46B EV / Sales 2026 *
23.6x
EV / Sales 2027 * 5.12x
Free-Float
87.16%
Yield 2026 *
-
Yield 2027 * -
1 day+113.68%
Current year+113.68%
Current year 20
Extreme 20
20
1 year 20
Extreme 20
20
3 years 5.22
Extreme 5.22
20
5 years 2.1
Extreme 2.1
20
10 years 1.8
Extreme 1.801
27.5
Manager TitleAgeSince
Chief Executive Officer 62 15/05/2012
Director of Finance/CFO - 01/01/2012
Chief Operating Officer - 01/01/2022
Director TitleAgeSince
Director/Board Member 62 15/05/2012
Director/Board Member - 01/04/2023
Director/Board Member - 17/04/2024
Change 5-day change 1-year change 3-year change Capi.($)
+113.68%-.--% - - 205M
+4.16%-0.36%+49.37%+94.17% 74.46B
-0.61%+0.69%+36.36%+82.72% 60.14B
-2.54%-0.21%+6.34%+31.72% 48.15B
-3.02%-5.20%+27.94%+34.47% 44.25B
+0.31%+3.02%+348.95%+686.74% 43.99B
-1.96%-0.33%+7.04%+100.99% 41.61B
+3.32%+3.49%+11.18%+51.23% 29.97B
+4.77%+6.16%+36.77%+22.78% 29.31B
-4.86%-10.66%-26.27%+328.03% 24.93B
Average +11.33%+1.97%+55.30%+159.21% 44.09B
Weighted average by Cap. +0.24%+1.83%+60.00%+150.79%

Financials

2026 *2027 *
Net sales 8.49M 9.56M 7.94M 7.23M 13.62M 920M 13.8M 96.02M 37.17M 469M 35.88M 35.1M 1.5B 39.86M 44.88M 37.28M 33.97M 63.96M 4.32B 64.84M 451M 175M 2.2B 169M 165M 7.07B
Net income -29.99M -33.77M -28.05M -25.56M -48.12M -3.25B -48.78M -339M -131M -1.66B -127M -124M -5.32B -1.96M -2.2M -1.83M -1.67M -3.14M -212M -3.18M -22.13M -8.57M -108M -8.27M -8.09M -347M
Net Debt 14.21M 16M 13.29M 12.11M 22.8M 1.54B 23.11M 161M 62.23M 784M 60.07M 58.76M 2.52B 18.13M 20.41M 16.96M 15.45M 29.09M 1.97B 29.49M 205M 79.41M 1B 76.65M 74.98M 3.22B
Logo Newron Pharmaceuticals S.p.A.
Newron Pharmaceuticals SpA is an Italy-based company operating in the medical research sector. It is a biopharmaceutical company focused on the research, development, and commercialization of therapies for disorders of the central and peripheral nervous system (CNS). The Company specializes in neurological and psychiatric diseases, including schizophrenia and Parkinson’s disease. Its activities include drug discovery, clinical development, regulatory approval processes, and strategic licensing and commercialization partnerships with pharmaceutical companies worldwide. The Company has built a pipeline comprised of drug candidates at different clinical stages and has a proven track record of drug development and commercialization, such as evenamide, safinamide and ralfinamide. Newron Pharmaceuticals SpA operates at global level.
Employees
27
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
8.496EUR
Average target price
50.62EUR
Spread / Average Target
+495.84%

Quarterly revenue - Rate of surprise